Pasadena, California-based Genervon Biopharmaceuticals, which recently completed a Phase IIa trial for their proprietary drug candidate GM604 in ALS, has now announced the results of the biomarker data from the trial. GM604 is a peptide master regulator that crosses the blood-brain-barrier and regulates several developmental pathways related to inflammation, hypoxia and apoptosis (see June 2013 news). The company reports that six of the eight biomarkers monitored during the trial suggest that G604 is modifying disease. These are particularly encouraging data considering that the clinical trial was of short duration – only two weeks of treatment followed by a 10 week observation period. Hopefully these promising biomarker results are also reflected in the patient outcome data, which is expected later this year.
Click here to read more.Share this: